NCT01006941
Completed
Phase 2
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
ConditionsRelapsing Multiple Sclerosis
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Relapsing Multiple Sclerosis
- Sponsor
- Rigshospitalet, Denmark
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- MRI activity judged by the number of new or enlarging T2 lesions, number of Gd enhancing lesions and volume of T2 lesions
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The hypothesis of this study is that treatment with Trichuris suis ova will be safe and effective as an oral treatment of patients with relapsing multiple sclerosis.
Investigators
Ana Voldsgaard
MD
Rigshospitalet, Denmark
Eligibility Criteria
Inclusion Criteria
- •age between 19 and 55 years
- •relapsing course of multiple sclerosis (relapsing-remitting or secondary progressive MS with relapses
- •duration of the disease of at least 1 year
- •no disease modifying therapy or unchanged immunomodulatory therapy for the last 3 months
- •at least 2 documented relapses during the last 24 months with the last relapse within the last 12 months
Exclusion Criteria
- •pregnancy or period of breastfeeding or missing adequate contraceptive protection for female premenopausal patients
- •relapse in the last month prior enrolment
- •treatment with steroids in the last 30 days
- •previous treatment with mitoxantroneduring the last year
- •previous treatment with cyclophosphamide or other intensive immunosuppression, total irradiation
- •treatment with glatiramer acetate, azathioprine, IVIG or any other immunosuppressive or immunomodulatory drug apart from interferon-beta in the 6 months prior to enrolment
- •cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, instable or advanced ischemic heart disease (CCS III or IV), malignant hypertension
- •diabetes mellitus and other autoimmune diseases
- •history of renal insufficiency
- •stay in tropical areas during the last 3 months
Outcomes
Primary Outcomes
MRI activity judged by the number of new or enlarging T2 lesions, number of Gd enhancing lesions and volume of T2 lesions
Time Frame: every 3. week. 3 MRI before treatment and 4 MRI during and after treatment
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 2
Trichuris Suis Ova Treatment in Left-sided Ulcerative ColitisColitis, UlcerativeNCT01953354National Institute of Allergy and Infectious Diseases (NIAID)16
Active, not recruiting
Phase 1
Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS ARelapsing Multipel SclerosisMedDRA version: 12.0Level: LLTClassification code 10028245Term: Multiple sclerosisMedDRA version: 12.0Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 12.0Level: LLTClassification code 10053395Term: Progressive multiple sclerosisEUCTR2008-007549-29-DKDanish Multiple Sclerosis Research Center10
Active, not recruiting
Phase 1
Treatment with eggs of pig whipworm for patients with rheumatoid arthritis, who are insufficiently treated with methotrexateRheumatoid arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2011-006344-71-DEImmanuel Krankenhaus Berlin50
Not yet recruiting
Phase 1
Trichuris suis ova (TSO) as an additional therapy for rheumatoid arthritis patients with insufficient response to methotrexate. A prospective, double-blind, randomized, controlled monocenter studyOther rheumatoid arthritisM06M05Seropositive rheumatoid arthritisDRKS00005323Immanuel Krankenhaus Berlin50
Completed
Phase 1
Trichuris Suis Ova in Peanut and Tree Nut AllergyFood AllergyNCT01070498Beth Israel Deaconess Medical Center18